乳腺癌女性的激素治疗转换。
Switching of Hormone Therapies in Breast Cancer Women.
机构信息
Faculty of Pharmaceutical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil.
Graduate Program in Medical Sciences, Faculty of Medical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil.
出版信息
Rev Bras Ginecol Obstet. 2021 Mar;43(3):185-189. doi: 10.1055/s-0040-1719149. Epub 2021 Jan 19.
OBJECTIVE
The objective of the present study was to analyze the reasons that led to hormone therapies (HTs) regimen changes in women with breast cancer.
METHODS
This was a retrospective cross-sectional study from a single-institution Brazilian cancer center with patient records diagnosed with breast cancer between January 2012 and January 2017.
RESULTS
From 1,555 women who were in treatment with HT, 213 (13.7%) women had HT switched, either tamoxifen to anastrozole or vice-versa. Most women included in the present study who switched HT were > 50 years old, postmenopausal, Caucasian, and had at least one comorbidity. From the group with therapy change, 'disease progression' was reason of change in 124 (58.2%) cases, and in 65 (30.5%) patients, 'presence of side effects' was the reason. From those women who suffered with side effects, 24 (36.9%) had comorbidities.
CONCLUSION
The present study demonstrated a low rate of HT switch of tamoxifen to anastrozole. Among the reasons for changing therapy, the most common was disease progression, which includes cancer recurrence, metastasis or increased tumor. Side effects were second; furthermore, age and comorbidities are risk factors for side effects.
目的
本研究的目的是分析导致乳腺癌患者激素治疗（HT）方案改变的原因。
方法
这是一项来自巴西单一癌症中心的回顾性横断面研究，对 2012 年 1 月至 2017 年 1 月期间诊断为乳腺癌的患者进行了病例记录。
结果
在接受 HT 治疗的 1555 名女性中，有 213 名（13.7%）女性的 HT 方案发生了改变，即从他莫昔芬改为阿那曲唑或反之。本研究中大多数接受 HT 方案改变的女性年龄>50 岁，绝经后，白种人，至少有一种合并症。在改变治疗方案的患者中，“疾病进展”是 124 例（58.2%）改变的原因，65 例（30.5%）患者改变的原因是“存在副作用”。在因副作用而停药的女性中，有 24 例（36.9%）有合并症。
结论
本研究显示，他莫昔芬转为阿那曲唑的 HT 转换率较低。在改变治疗方案的原因中，最常见的是疾病进展，包括癌症复发、转移或肿瘤增大。其次是副作用；此外，年龄和合并症是副作用的危险因素。
Zotero 插件